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ABSTRACT 
 
 Nano-sized materials have been widely used in many products, such as painting 
materials, cosmetics, and drug cargos. Especially in biological applications, nanoparticles 
work as drug delivery carriers in recent decades due to their features on size and transport 
properties compared to drug molecules alone. Modification of nanoparticle surface, 
structure, and its fabrication methods has been done by researchers to improve the 
loading efficiency and targeting performance. However, the retention of nanoparticles on 
the targeted tissue is still a big challenge. After injection, drug loaded nanoparticles are 
rapidly washed away in the area of drug delivery due to high local velocity, which limits 
the drug release on the desired site. In this study, we hypothesized that the nanoparticles 
are able to coat over the microbubble surface spontaneously through van der Waals 
attraction without any chemical or electrical modification on the particle surface, where 
the microbubble were self-assembled by the amphiphilic polymer. Microbubbles are 
commonly used as ultrasound contrast agents, and the limited life time of microbubbles is 
the major challenge for microbubble applications. The coating of the nanoparticles 
enhanced the microbubbles’ stability, and at the same time, the microbubbles helped to 
reduce the movement of the nanoparticles. Moreover, the immobilization of nanoparticles 
improved the performance of nanoparticle retention and the effect of drug deliver. The 
results provide a new strategy of the co-existence of micro- and nano-scaled particles 
without the additional surface tailoring and a new research direction of the improved drug 
retention on targeted tissue.   
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Chapter 1 
INTRODUCTION 
 
1.1 Background and Motivation 
In recent decades, tons of studies on micro- and nano-sized materials have been 
done, and nanoparticles have been involved within daily life in many aspects, such as 
painting material, cosmetics, and food.(1-3) Among these developments, the use of 
nanoparticles in biological application has drawn a lot of attention. As a biocompatible 
material, the big potential market of nanoparticles in biological applications has expanded 
fleetly.(4-6) Nanoparticles are capable of loading drug molecules of interests and also 
sustainably releasing the molecules. They have been extensively studied to improve 
quality of molecular therapies because nanoparticles’ uniquely size enables minimally 
invasive delivery via simple intravenous or intramuscular injection. It is well agreed that 
the successful use of nanoparticles in drug delivery greatly relies on a capability to retain 
the particles in target tissue over a desired treatment time period.(7-11) However, 
nanoparticles are readily displaced from the implanted site, particularly when the area is 
subject to external mechanical force. The resulting increase of drift velocity becomes 
more significant with smaller particles. Therefore, there is a great need to improve a 
nanoparticle retention level in a target tissue defect or pathologic tissue.(12-14) 
To resolve such challenges, certain efforts were made to reduce mobility of 
nanoparticles following injection. For example, nanoparticles were mixed with a pre-gel 
solution to be entrapped in the gel, where the gel can prevent displacement of 
nanoparticles. To further improve retention of nanoparticles in a gel, nanoparticle surface 
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was modified to electrostatically associate with gel-forming polymers. However, this 
approach was often fraught by reduced molecular release rate, because the gel matrix 
acted as a physical barrier that decreased diffusivity of drug molecules following the 
release from nanoparticles. Alternatively, surface potential of nanoparticles was 
engineered to induce electrostatic attraction between them, so the nanoparticles are self-
assembled to form a colloidal gel following injection.(15,16) However, surface potential of 
nanoparticles may negatively influence drug release rate via uncontrolled electrostatic 
interaction. Therefore, there are grand interests in reducing nanoparticle mobility without 
loading them in a gel matrix or altering surface potential of nanoparticles. 
To this end, we hypothesized that van der Waals force-induced loading of 
nanoparticles onto surface of sacrificial, micro-sized polymeric bubbles with tissue 
epithelium would allow us to significantly elevate nanoparticle retention level at injected 
sites, even without altering surface potential of nanoparticles.   
 
1.2 Research Plan 
 In this study, we examined the hypothesis by using microbubbles with an average 
diameter of about 50 µm, formed from self-assembly of alkylated polyaspartamide as a 
model of sacrificial microbubbles. The poly(lactic-co-glycolic acid) (PLGA) 
nanoparticles with an average diameter of about 100 nm was used as a model of drug-
loaded nanoparticles. Due to the difference in the diameters of microbubbles and 
nanoparticles by two orders of magnitude, van der Waals attraction between microbubble 
and nanoparticle becomes larger than the attraction between PLGA nanoparticles. The 
role of microbubbles in improving retention level of PLGA nanoparticle was evaluated 
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by implanting the fluorescent nanoparticle-coated microbubbles onto chicken 
chorioallantoic membranes (CAMs) and quantifying the fluorescent intensity. The effect 
of nanoparticle retention on drug efficacy was further evaluated by using PLGA 
nanoparticles laden with angiopoetin-1 on CAMs and examining the degree of 
neovascularization.   
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Chapter 2 
MATERIALS AND METHODS 
 
2.1 Synthesis and characterization of PHEA-g-C18 
 Briefly, poly(succinimide) (PSI, Mw 19,000 g/mol, PDI 1.5) was the starting 
chemical, synthesized through the acid-catalyzed polycondensation process of L-aspartic 
acid (Sigma-Aldrich) described previously.(17) The L-aspartic acid was dissolved in dried 
sulfolane with existence of 85% phosphoric acid as the catalyst to generate PSI with 
molecular weight of 19,000 g/mol. The reaction happened at 170 °C for 7 hours, refluxed 
under dry nitrogen atmosphere with Dean-Stark trap setup (Figure 2.1). The color change 
was observed while the reaction was going on. After the reaction was done, the 
precipitation was filtered out, and washed with methanol and deionized water in sequence 
till it was neutral. Then dialyze (Fisher Scientific, MWCO 3,500) the product against 
deionized water for two days and freeze dry (Labconco, FreeZone 6) to obtain dry 
powder.  
By aminolysis, PSI was functionalized with octadecylamine (ODA) (Sigma-
Aldrich) and ethanolamine (Sigma-Aldrich) sequentially into poly(2-hydroxyethyl 
aspartamide) grafted with octadecyl chains (PHEA-g-C18).
(18) PSI, dissolved in 
dimethylformamide (DMF) at concentration of 1.5 mmol PSI per 5 mL DMF, was 
reacted with the calculated amount of ODA at 70 °C for 24 hours with continuous 
stirring. After the mixture was cooled down to the room temperature, the calculated 
volume of ethanolamine was added dropwise and further reacted for 6 hours. The final 
product was collected and purified via dialysis (Fisher Scientific, MWCO 3,500) against 
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deionized water for 2 days followed by freeze-drying (Labconco, FreeZone 6) to obtain 
the dry powder.  
The structure of PHEA-g-C18 was characterized by 
1H NMR spectra, from which 
the degree of substitution of octadecyl chains (DSC18) on the PHEA backbone was 
calculated by using [Eq. (1)]: 
𝐷𝑆𝐶18 =
𝐼𝑛𝑡𝑒𝑔𝑟𝑎𝑡𝑖𝑜𝑛 𝑜𝑓 𝑠𝑝𝑒𝑐𝑡𝑟𝑎 𝑓𝑟𝑜𝑚 0.80 𝑡𝑜 0.86 /3
𝐼𝑛𝑡𝑒𝑔𝑟𝑎𝑡𝑖𝑜𝑛 𝑜𝑓 𝑠𝑝𝑒𝑐𝑡𝑟𝑎 𝑓𝑟𝑜𝑚 4.36 𝑡𝑜 4.70
.                   Eq. (1) 
where the integration of spectra from 0.80 ppm to 0.86 ppm represents the methyl group 
on octadecyl chain containing three protons; the integration of spectra from 4.36 ppm to 
4.7 ppm represents the proton on the polymer backbone with one per polymer unit. 
 
 
2.2 Formation of microbubbles 
Pre-microbubble solution was prepared by dissolving PHEA-g-C18 in deionized 
water at concentrations of 0.1% w/w, 0.5% w/w and 1% w/w in 1.5 mL Eppendorf tube 
with necessary Vortex touch mixing (Scientific Industries) and bath sonication (Fisher 
Scientific, FS60). To form bubbles, the probe sonicator (Fischer Scientific, Sonic 
Dismembrator Model 100) was applied, where the tip of the sonicator probe was placed 
about 2 mm under the liquid surface (Figure 2.2). Under the average output power of 6 
watts for 30 seconds, a foam layer of microbubbles was generated. Followed by the 
fabrication of non-coating microbubbles described previously, the microbubbles coated 
with functionalized PLGA nanoparticles were prepared by carefully replacing the 
deionized water media with prepared 0.5% w/w PLGA nanoparticle solution.  
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2.3 Characterization of microbubbles 
 The diameters of microbubbles at different concentrations and different time 
points were measured through optical microscope images (Leica, DMIL) by using 
ImageJ. The microbubble sample was fixed on the surface of agar gel to immobilize the 
microbubbles for imaging. The agar gel was prepared by dissolving agar powder (Sigma) 
in deionized water at 10% w/w and heating the suspension at 85 °C till it was clear. Then 
pour the pre-gel solution into a Petri dish and gently transfer microbubbles in the center 
of the gel surface. The sample was ready to use till the gel was completed congealed.   
To analyze the stability of microbubbles, the microbubble solution was kept in 1.5 
mL Eppendorf tube and incubated at 37 °C overtime. A certain amount of microbubble 
was taken from each sample at the time point of 0 hour, 1 hour, and 3 hours, and the 
diameters were measured from optical microscopy images (Leica, DMIL) with Image J. 
The PLGA nanoparticle coating on the microbubble surface was observed with confocal 
microscopy images (Zeiss, LSM700), while PLGA nanoparticles were labeled with 
fluorescein isothiocyanate (FITC) (Sigma-Aldrich). 
 
 
2.4 Preparation of PLGA nanoparticles 
Nano-sized PLGA particles were generated through nanoprecipitation process, 
where the solution of PLGA (Direct) in acetone was added dropwise into deionized water 
with continuous stirring. After the precipitation, the organic solvent was evaporated 
under fume hood over night or by rotary evaporator, and the PLGA nanoparticles were 
dried via lyophilization (Labconco, FreeZone 6). For fluorescent PLGA nanoparticles, 
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FITC was added at the step of dissolving PLGA in acetone. For angiopoietin-1 loaded 
PLGA nanoparticles, a certain amount of angiopoietin-1 was dissolved and diluted in 1x 
phosphate buffered saline (1x PBS). Instead of dropping solution of PLGA in acetone 
into deionized water, the polymer solution was added into 1x PBS solution of 
angiopoietin-1 dropwise. 
 
 
2.5 Retention test of nanoparticles  
 Chick chorioallantoic membrane (CAM) assay was used to analyze the retention 
behavior of the fluorescent PLGA nanoparticles at the conditions with and without 
microbubbles. The eggs were one week old, fertilized chicken embryos from the farm. A 
window with the diameter about 1 cm on the egg shell was opened one day before the 
sample implantation. Samples were placed onto the CAMs and incubated at 37°C. During 
the incubation, the window on the egg shell was always covered with a piece of 
transparent tape. After time points of 1 hour, 1 day, and 7 days, CAMs of three eggs for 
each condition were excised at the implantation area after adding 2 mL 3.7% v/v 
formaldehyde (Sigma-Aldrich) and storing at 4 °C for an hour. Then the CAMs were cut 
out from the eggs and kept in Petri dishes with sufficient amount of 3.7% v/v 
formaldehyde (Figure 2.3). The distribution of fluorescent PLGA nanoparticles on CAMs 
were observed with confocal microscopy images (Zeiss, LSM700), and the total 
fluorescent areas and the nanoparticle aggregation areas were quantified by MATLAB 
code developed by the author. 
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2.6 Angiogenesis with angiopoietin-1 loaded particles 
 Angiopoietin-1 loaded PLGA nanoparticles with or without microbubbles were 
implanted onto the CAMs followed by the CAM assay process described in session 2.5. 
Instead of excising the eggs at different time points, all the eggs were sacrificed after 7 
days for angiogenesis study. Here, 1x PBS was used as a control group without any 
elevating on vascularization. The excised CAMs on day 7 were embedded in paraffin, 
sectioned, and stained with an antibody to α-smooth muscle actin (α-SMA) for 
histological study. The images of CAM cross sessions were taken with the optical 
microscope (Leica, DMIL), and the number of the blood vessels with cross sectional area 
less than 500 µm2 was quantified by Image J.    
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2.7 Figures 
 
Figure 2.1. The experiment setup of the acid-catalyzed polycondensation of L-aspartic 
acid to form PSI with Dean-Stark trap. 
 
 
 
 
 
 
 
 
 
Figure 2.2. The experiment setup of microbubble generation by probe sonication. 
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Figure 2.3. The scheme of CAM experiment for retention and angiogenesis evaluation.  
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Chapter 3 
RESULTS AND DISCUSSION 
 
3.1 Preparation and characterization of polymeric microbubbles 
Microbubbles were formed via self-assembly of amphiphilic polymer – poly(2-
hydroxyethyl aspartamide) grafted with octadecyl chains, termed as PHEA-g-C18. In the 
first step, polycondensation of L-aspartic acid with acid catalyst led to polysuccinimide 
(PSI). Secondly, PSI was substituted with octadecylamine and ethanolamine to form 
PHEA-g-C18 by aminolysis reactions, where the hydroxyl groups acted as the hydrophilic 
component and the alkyl chains acted as the hydrophobic component (Figure 3.1a).(17,18) 
At a molar ratio between octadecylamine and succinimidyl units of PSI at 15%, the final 
degree of substitution for octadecyl chains (DSC18) was 12.2 mol% as quantified with 
peaks from 0.80 to 0.86 ppm and peaks from 4.36 to 4.70 ppm in from 1H NMR spectra 
by using Eq(1) (Figure 3.1b). Note that peaks from 0.80 to 0.86 ppm represent protons of 
methyl groups at the end of the C18 chains containing three protons and those from 4.36 
to 4.70 ppm do PHEA backbones containing one proton per PSI unit.  
The resulting, amphiphilic PHEA-g-C18 was able to self-assemble into 
microbubbles by sonication applied at the interface of air and polymer solution (Figure 
3.2). Particularly, microbubbles were assembled with polymer solutions at three different 
concentrations of the polymer solution to control size and stability (Figure 3.3a). 
Increasing concentration of the polymer solution from 0.1% to 0.5% w/w decreased the 
initial average diameter of microbubbles. The sizes of microbubbles were quantified with 
optical images, and as the result, as the concentration increases, the average diameter of 
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the microbubbles decreased from 194 ± 103 µm to 49 µm ± 36 µm. Further increasing 
the polymer concentration to 1% w/w made the minimal changes of the initial diameter of 
microbubbles; however, it contributed to improving the stability of bubbles incubated at 
37 °C. Over 3 hours, the microbubbles prepared with 1% w/w polymer solution 
undertook a two-fold smaller increase of the diameter compared to the ones with 0.5% 
w/w polymer solution (Figure 3.3b).  
It suggested that sonication applies enough energy to direct hydrophobic 
association of octadecyl chains of PHEA in oil phase with air molecules. Then, the 
polymers surround air molecules to reduce the thermodynamic free energy. Finally, 
hydroxyl groups of PHEA-g-C18 likely facilitate dispersion of microbubbles in aqueous 
media. Therefore, similar to a surfactant, increasing concentration of PHEA-g-C18 from 
0.1% to 0.5% w/w should lead to an increase of the curvature of microbubbles. The 
minimal change of the microbubble size with an increase of polymer concentration from 
0.5% to 1% w/w indicates that polymer association with air molecules is saturated at 
0.5% w/w. The significantly enhanced microbubble stability marked by a smaller size 
increase implicates that excess PHEA-g-C18 in the media prevents association between 
microbubbles and subsequent fusion. 
 
 
3.2 Modification of microbubbles coated with PLGA nanoparticles 
Monodisperse PLGA nanoparticles with an average diameter of 100 nm were 
prepared via nanoprecipitation. Mixing aqueous suspension of PLGA nanoparticles with 
freshly made microbubbles resulted in microbubbles spontaneously covered by PLGA 
  13 
nanoparticles (Figure 3.4a). According to fluorescence imaging of PLGA nanoparticles 
labeled with fluorescein isothiocyanate (FITC) in free suspension and co-existence with 
microbubbles, nanoparticles were clearly localized on surface of microbubbles (Figure 
3.4b and 3.4c). Even after the exposure to shear flow to simulate injection process, the 
nanoparticles were stably bound to the microbubble. 
It is suggested that the association between microbubbles and nanoparticles are 
driven by van der Waals attraction forces, due to significantly different size by one order 
of magnitude [Eq. (2)]: 
𝑉𝐴 = −
𝐴
6𝐷
𝑅1𝑅2
𝑅1+𝑅2
                                                Eq. (2) 
where 𝑅1 and 𝑅2 are the radii of microbubbles and nanoparticles respectively; 𝐴 is the 
Hamaker constant with unit of Joule; VA is van der Waal potential; and D is the distance 
between two particles.(19) The Hamaker constants of PHEA-g-C18 and PLGA were 
considered 6.5 × 10−20  J.(20) The estimated attractive energy potential between PLGA 
nanoparticle and microbubble is about twice of that between two PLGA nanoparticles, 
and the size of microbubbles did not really affect the van der Waal potential (Table 3.1). 
More interestingly, the mirocbubbles coated with PLGA nanoparticles remained 
more stable than plain microbubbles in a physiologically relevant condition. At 37 °C, the 
microbubbles prepared with 1% w/w PHEA-g-C18 solution undertook a three-fold smaller 
increase of the diameter than bare microbubbles (Figure 3.5a). With the nanoparticle 
coating, all most the whole population of microbubbles was within the diameter smaller 
than 50 µm at the beginning; even after 3 hours, there were still around 70% of 
microbubbles in the range within 50 µm. In contrast, without nanoparticle coating, only 
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about 70% of microbubbles appeared with less than 50 µm in diameter; after 3 hours, the 
majority of bare microbubbles was in the range of 100 to 250 µm (Figure 3.5b). 
 
 
3.3 In vivo evaluation of PLGA nanoparticle retention 
The PLGA nanoparticles and those associated with microbubbles, both of which 
were labeled with fluorescent molecules FITC, were placed on chicken chorioallantoic 
membrane (CAM), in order to evaluate retention level of PLGA nanoparticles with 
fluorescence. According to fluorescence imaging of the CAMs captured after 
implantation, both two conditions displayed minimal change of fluorescence yield after 
one hour of implantation (Figure 3.6a). Given that fluorescent molecules were conjugated 
with PLGA nanoparticles, this result implicates that nanoparticle displacement was 
minimal during first one hour (Figure 3.6b).  
However, between Day 1 and Day 7, the total fluorescence from PLGA 
nanoparticles implanted without being associated with microbubbles rapidly decreased 
(Figure 3.6c). According to the quantification with fluorescence yield, approximately 
90% of PLGA nanoparticles were displaced from the implanted site without 
microbubbles. In contrast, the nanoparticles associated microbubbles exhibited no 
significant decrease of fluorescence over 7 days. Overall, almost all PLGA nanoparticles 
were remained in the implanted site due to microbubbles.   
 Given that PHEA-g-C18 microbubbles are collapsed within a few hours of 
implantation, but the majority of polymers remain at the implantation site. We suggest 
that PHEA-g-C18 from the collapsed microbubbles hydrophobically associate with 
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epithelium of CAMs to reduce the PLGA nanoparticle movement; in contrast, without 
microbubbles and PHEA-g-C18, PLGA nanoparticles are quickly replaced and aggregate 
in small groups on CAMs (Figure 3.7a and 3.7b). Therefore, it is likely that the PHEA-g-
C18 could reduce the number of PLGA nanoparticles displaced by mechanical 
deformation of CAM caused by an embryo’s heart contraction. Additionally, the minimal 
difference of the number of PLGA nanoparticles between two conditions at Hour 1 
implicates that free PLGA nanoparticles could initially associate with CAMs. However, 
the adhesion strength of PLGA nanoparticles to CAMs is likely smaller than that to 
PHEA-g-C18 microbubbles, due to the absence of hydrophobic alkyl chains on its surface 
as well as higher mobility. In this regard, the conjugation of alkyl chains to PLGA 
nanoparticle surface may reduce nanoparticle displacement even without the appearance 
of PHEA microbubbles. However, the underlying chemistry may negatively impact 
encapsulation efficiency and bioactivity of encapsulated drug molecules. In this regard, it 
would be advantageous to separately use PLGA nanoparticles as a drug carrier and 
PHEA-g-C18 microbubbles as a tissue glue. 
 
 
3.4 In vivo evaluation of vascularization induced by Angiopoietin-1 loaded PLGA 
nanoparticles 
 To demonstrate the importance of the retention of drug-releasing PLGA 
nanoparticles in therapies, PLGA nanoparticles loaded with Angiopoietin-1. 
Angiopoietin-1 is known to stimulate angiogenesis by activating Tol-like receptors of 
endothelial progenitor and precursor cells.(21) The Angiopoietin-1 loaded in the PLGA 
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nanoparticles are sustainably released within first five days, so they can stimulate host 
blood vessel-forming cells. The Angiopoietin-1 encapsulating PLGA nanoparticles 
further associated with PHEA-g-C18 microbubbles were implanted on the CAM, as well 
as control conditions including PBS buffer and mirobubble-free Angiopoietin-1 releasing 
PLGA nanoparticles.  
 According to cross-sectional histological images of the CAM stained for alpha-
smooth muscle actin layer on mature blood vessels, the membranes implanted with 
Angiopoietin-1-releasing PLGA nanoparticles presented about five-fold larger number of 
mature blood vessels with cross-sectional area between 30 and 400 µm2 those injected 
with PBS (Figure 3.8). In contrast, CAM implanted with PLGA nanoparticles 
immobilized on the sacrificial PHEA-g-C18 microbubbles presented the more than six-
fold increase of the number of mature blood vessels.  In addition, the microbuubles 
contributed to improving neovascularization efficacy of Angiopoietin-1 releasing PLGA 
nanoparticles by three times (Figure 3.9).  
 We interpret that such enhanced neovascularization using PLGA nanoparticles 
immobilized on microbuubles is well correlated to the improved retention of PLGA 
nanoparticles at an implantation site, as displayed in Figure 3. The Angiopoietin-1-
releasing, bare PLGA nanoparticles do not chemically or physically interact with 
epithelium that constitute CAM. Therefore, the nanoparticles are likely displaced from 
the implanted site, thus reducing bioavailability of Angiopoietin-1. In contrast, PLGA 
nanoparticles remained at the implantation site due to association with PHEA-g-C18 
microbubbles should be able to increase concentration of Angiopoietin-1 and activating 
cellular signaling involved with endothelial sprouts and smooth muscle cell recruitment. 
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It is well agreed that density and quality of newly-forming blood vessels are significantly 
dependent on the duration of proangiogenic growth factors. We believe that such 
nanoparticle delivery strategy using microbubbles would be used for a variety of growth 
factors known to stimulate tissue regeneration. There material systems will be ultimately 
contribute to improving quality of various wounds and tissue defects with reduced dosage 
of growth factors. 
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3.5 Figures and Tables 
 
Figure 3.1. Synthesis of PHEA-g-C18 microbubbles. (a) The reaction scheme of PHEA 
(green) functionalized with octadecyl chains (C18) (orange). (b) 
1H NMR spectra of 
PHEA-g-C18 with integration.  
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Figure 3.2. Scheme of microbubble formation by probe sonication at molecular level: 
After sonication at the interface of air and polymer aqueous solution, the alkyl chains 
were towards the air core regarded as an oil phase, and the hydroxyl groups on the 
polymer backbone stabilized the microbubbles in aqueous phase.  
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Figure 3.3. Characterization of PHEA-g-C18 microbubbles. (a) Optical microscopy 
images of microbubbles prepared with solution of three different PHEA-g-C18 
concentrations. The bubbles were captured at different time points while incubating them 
in deionized water. Scale bar represents 200 µm. (b) The growth trend of microbubbles at 
conditions of 0.5% and 1% w/w over 3 hours. With 0.5% w/w solution, 512, 231, and 63 
microbubbles were measured respectively at 0 hour, 1 hour, and 3 hours; with 1% w/w 
solution, 514, 349, and 126 microbubbles were measured respectively at 0 hour, 1 hour, 
and 3 hours. 
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Figure 3.4. Modification of microbubbles coated with PLGA nanoparticles. (a) The 
schematic structure of microbubbles (the blue sphere) coated with PLGA nanoparticles 
(the purple spheres). (b) The confocal microscopy image of pure FITC-labeled PLGA 
nanoparticles. (c) The confocal microscopy image of microbubbles coated with FITC-
labeled PLGA nanoparticle. 
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Figure 3.5. Size analysis of micorbubbles with and without PLGA nanoparticle coating. 
(a) The growth trend of microbubbles made of 1% w/w polymer solution at both 
conditions with and without PLGA nanoparticle coating, incubated at 37 °C for 3 hours. 
(b) The histogram of microbubbles at 0 hour and 3 hours with and without PLGA 
nanoparticles. (MBs: microbubbles; MBs + PLGA NPs: microbubbles coated with PLGA 
nanoparticles.) 
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Figure 3.6. In vivo evaluation of PLGA nanoparticle retention. (a) The confocal 
microscopy images of CAMs incubated with FITC-labeled PLGA nanoparticles with and 
without microbubbles at different time points. (b) The quantified aggregation fraction for 
each condition. (c) The quantified fraction of remaining PLGA nanoparticles for each 
condition. 
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Figure 3.7. Proposed scheme of PLGA nanoparticles on CAMs with and without 
microbubbles. (a) PLGA nanoparticles without microbubbles replace and aggregate 
quickly overtime. (b) PLGA nanoparticles are localized by microbubbles and associated 
with polymer after bubble rapture. 
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Figure 3.8. Histological images of CAM cross sessions at three different conditions.  
(PLGA-Ang1 NPs: Angiopoietin 1-loaded PLGA nanoparticles; MBs + PLGA-Ang1 
NPs: microbubbles coated with Angiopoietin 1-loaded PLGA nanoparticles.) 
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Figure 3.9. Quantified number of blood vessels with cross sectional area less than 500 
µm2 per 1 mm2 tissue area. (*: statistical p value less than 0.05; 9 samples were measured 
for each condition.) 
 
 
 
 
 
 
 
 
 
Table 3.1. Analysis of van der Waals potential for different particle interaction  
 R1 (µm) R2 (µm) VA (10-20 J) 
Nanoparticle - 
Microbubble 
0.05 5 -53.6 
0.05 50 -54.1 
0.05 100 -54.1 
Nanoparticle - 
Nanoparticle 
0.05 0.05 -27.1 
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Chapter 4 
CONCLUSION 
 
4.1 Summary 
 The study demonstrated the nanoparticle coating on microbubbles through van der 
Waals attraction by simply replacing the media without any further surface modification. 
The coating of nanoparticles on microbubble surface prolonged the microbubble life time 
by effectively reducing the direct interaction between microbubbles. Besides the coating, 
the size and stability of microbubbles was also related to the concentration of polymer 
solution; the initial size of microbubbles did not change much after certain point, but the 
stability was enhanced with high packing density of polymers. Along with the improved 
stability of microbubbles with nanoparticle coating, microbubbles helped to localize the 
nanoparticles with minimalized aggregation. With nanoparticles loaded with 
angiopoietin-1, the microbubbles helped to enhance the drug release performance over 
time at the desired sites. The CAM assay showed that drug-loaded nanoparticles co-
existed with microbubbles initiated evenly distributed blood vessels, which was helpful 
on setting up new blood vessel network for nutrient transport.  
 
 
4.2 Future Work 
 For future studies, it will be important further stabilize the microbubbles to reach 
the better result on localizing the drug-loaded nanoparticles. The stabilization of 
microbubbles can be done through modifying the polymer with polyethylene glycol, 
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which is widely used to prolong the life time of nanoparticles in physiological condition. 
Furthermore, to test the efficacy of the microbubble-nanoparticle system with 
vascularization drug on damaged tissue is important to confirm that evenly initiated blood 
vessel network works better in tissue repairing. 
Furthermore, due to features of microbubbles, we suggest to apply this drug 
delivery system, microbubbles combined with drug-loaded nanoparticles, coupled with 
ultrasound imaging since microbubbles are well known as ultrasound contrast agents or 
ultrasound triggered microbubble rapture to direct the drug delivery. In this regard, the 
system can be develop for imaging-guided drug delivery. 
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